Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ), in patients with relapsed or refractory mantle cell lymphoma (MCL).
暂无分享,去创建一个
J. Byrd | J. Leonard | I. Flinn | Jennifer R. Brown | D. Benson | S. Coutre | R. Furman | N. Wagner-Johnston | W. Godfrey | S. Spurgeon | B. Kahl | D. Johnson | R. Dansey | S. Peterman | Jessie P. Gu | J. Gu